February 2023 Top Biopharma Deal Upfront
February 22, 2023
$167M
$66M
N/A
N/A
$101M dev. and sales milestones
Undisclosed mid-twenties royalties
N/A
Axsome’s Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor
Development and Com. License
Collaborative Development, No Shared Cost
Axsome granted Pharmanovia exclusive rights to develop and commercialize Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor in Europe and certain Middle East and North Africa (MENA) countries for the treatment of excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Pharmanovia will be responsible for marketing Sunosi in Europe and MENA regions and will assume responsibility for all local clinical and regulatory activities.
Axsome will receive $66M up front and is eligible for up to $101M in sales and other milestones, plus undisclosed mid-twenties royalties.
Congrats to Axsome and Pharmanovia for landing DealForma’s February 2023 Top Biopharma Deal. Last month’s Deal of the Month was Hutchmed – Takeda for cancer drug fruquintinib.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.
Database
Company
Comparisons
Website Design by Once Interactive
